| NCT ID | NCT07652970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois Chicago |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-06-17 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-06-17 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine the effects of home-based cross-education on lower limb neuroplasticity in severe stroke. The main questions the investigators aim to answer are: * What are the effects of home-based cross-education on lower limb neuroplasticity? * What are the effects of home-based cross-education on lower limb function? * Is home-based cross-education feasible to administer and accepted by participants? Participants will take part in ten home-based, remotely supervised sessions, during which participants will either perform unilateral skill and strength training of the unaffected lower limb (Tele-Cross Education or Tele-CE) or cognitive training and unilateral movements of the unaffected lower limb (Tele-control). Each participant will experience measures of brain and spinal activity and motor function testing before and after both sessions (Tele-CE and Tele-control). Each participant will also be asked to fill out a feedback questionnaire to assess acceptability after intervention sessions (Tele-CE and Tele-control).
Eligibility Criteria
Inclusion Criteria: * Single, monohemispheric stroke * Chronic stroke (\> 6 months prior) * Severe stroke (Fugl-Meyer Lower Extremity motor scale score \< 21 or 6 Minute Walk Test distance \< 300m) Exclusion Criteria: * Use of anti-spasticity medications * Existence of other neurological disorders * Have brainstem or cerebellar lesions. * Mini-Mental State Examiniation score of \<21, to ensure participants have the cognitive capacity to consent and can understand instructions both in-person and during remote supervision. * Non-English-speaking individuals * Bone, joint or soft tissue injury * Uncontrolled medical conditions (such as uncontrolled hypertension, untreated cardiac disease, or untreated pulmonary disease) * Unable to see the tablet and zoom screen * Unable to move non-paretic ankle (\< 5 degrees of ankle ROM) * Fugl-Meyer Lower Extremity sensory scale score \< 6 TMS exclusion criteria * Previous adverse reaction to TMS * Skull abnormalities or fractures * Concussion within the prior 6 months * Unexplained, recurring headaches * Implanted cardiac pacemaker * Metal implants in the head or face * History of seizures or epilepsy * Use of medications that could alter cortical excitability or increase risk of seizure (e.g., antidepressants, antipsychotics, anxiolytics, anticonvulsants) * Current pregnancy PNS exclusion criteria * Skin hypersensitivity at any sites of stimulation, including the scalp, thoracolumbar spine, and peripheral limbs * History of contact dermatitis at any of the sites of stimulation * History of allodynia and/or hyperalgesia * Active skin infection * Skin lesions * Deep vein thrombosis * Any other skin or scalp condition that could be aggravated by stimulation * Implanted electronic, metallic, or highly conductive devices near site of stimulation that cannot be removed without permission from a health professional
Frequently Asked Questions
Who can join the NCT07652970 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07652970 currently recruiting?
Yes, NCT07652970 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Illinois Chicago to inquire about joining.
Where is the NCT07652970 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07652970 clinical trial?
NCT07652970 is sponsored by University of Illinois Chicago. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.